[1]
|
Sabattini, E., Bacci, F., Sagramoso, C., et al. (2010) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues in 2008: An Overview. Pathologica, 102, 83-87.
|
[2]
|
Kaur, V., Swami, A., Alapat, D., et al. (2018) Clinical Characteristics, Molecular Profile and Outcomes of Myeloid Sarcoma: A Single Institution Experience over 13 Years. Hematology, 23, 17-24.
https://doi.org/10.1080/10245332.2017.1333275
|
[3]
|
Almond, L.M., Charalampakis, M., Ford, S.J., et al. (2017) Myeloid Sarcoma: Presentation, Diagnosis, and Treatment. Clinical Lymphoma, Myeloma & Leukemia, 17, 263-267. https://doi.org/10.1016/j.clml.2017.02.027
|
[4]
|
Campidelli, C., Agostinelli, C., Stitson, R., et al. (2009) Myeloid Sarcoma: Extramedullary Manifestation of Myeloid Disorders. American Journal of Clinical Pathology, 132, 426-437. https://doi.org/10.1309/AJCP1ZA7HYZKAZHS
|
[5]
|
Peloquin, G.L., Chen, Y.-B. and Fathi, A.T. (2013) The Evolving Landscape in the Therapy of Acute Myeloid Leukemia. Protein & Cell, 4, 735-746. https://doi.org/10.1007/s13238-013-3057-2
|
[6]
|
Pui, M.H., Fletcher, B.D. and Langston, J.W. (1994) Granulocytic Sarcoma in Childhood Leukemia: Imaging Features. Radiology, 190, 698-702. https://doi.org/10.1148/radiology.190.3.8115614
|
[7]
|
Singh, A., Kumar, P., Chandrashekhara, S.H., et al. (2017) Unravelling Chloroma: Review of Imaging Findings. The British Journal of Radiology, 90, 20160710. https://doi.org/10.1259/bjr.20160710
|
[8]
|
Kamboj, M., Sharma, A., Gupta, G., et al. (2017) Isolated Myeloid Sarcoma of Cervix: Aleukemic Presentation. Journal of Cancer Research and Therapeutics, 13, 1076-1077.
|
[9]
|
Claerhout, H., Van Aelst, S., Melis, C., et al. (2018) Clinicopathological Characteristics of de Novo and Secondary Myeloid Sarcoma: A Monocentric Retrospective Study. European Journal of Haematology, 100, 603-612.
https://doi.org/10.1111/ejh.13056
|
[10]
|
Neiman, R.S., Barcos, M., Berard, C., et al. (1981) Granulocytic Sarcoma: A Clinicopathologic Study of 61 Biopsied Cases. Cancer, 48, 1426-1437.
https://doi.org/10.1002/1097-0142(19810915)48:6<1426::AID-CNCR2820480626>3.0.CO;2-G
|
[11]
|
Meyer, H.-J., Beimler, M., Borte, G., et al. (2019) Radiological and Clinical Patterns of Myeloid Sarcoma. Radiology and Oncology, 53, 213-218. https://doi.org/10.2478/raon-2019-0014
|
[12]
|
Aschoff, P., Häntschel, M., Oksüz, M., et al. (2009) Integrated FDG-PET/CT for Detection, Therapy Monitoring and Follow-Up of Granulocytic Sarcoma. Initial Results. Nuklearmedizin, 48, 185-191.
https://doi.org/10.3413/nukmed-0236
|
[13]
|
Zhang, X., Huang, P., Chen, Z., et al. (2019) Vulvar Myeloid Sarcoma as the Presenting Symptom of Acute Myeloid Leukemia: A Case Report and Literature Review of Chinese Patients, 1999-2018. Diagnostic Pathology, 14, Article No.: 126. https://doi.org/10.1186/s13000-019-0892-3
|
[14]
|
Pileri, S.A., Ascani, S., Cox, M.C., et al. (2007) Myeloid Sarcoma: Clinico-Pathologic, Phenotypic and Cytogenetic Analysis of 92 Adult Patients. Leukemia, 21, 340-350. https://doi.org/10.1038/sj.leu.2404491
|
[15]
|
Alexiev, B.A., Wang, W., Ning, Y., et al. (2007) Myeloid Sarcomas: A Histologic, Immunohistochemical, and Cytogenetic Study. Diagnostic Pathology, 2, Article No.: 42. https://doi.org/10.1186/1746-1596-2-42
|
[16]
|
Bakst, R.L., Tallman, M.S., Douer, D., et al. (2011) How I Treat Extramedullary Acute Myeloid Leukemia. Blood, 118, 3785-3793. https://doi.org/10.1182/blood-2011-04-347229
|
[17]
|
Tsimberidou, A.-M., Kantarjian, H.M., Wen, S., et al. (2008) Myeloid Sarcoma Is Associated with Superior Event- Free Survival and Overall Survival Compared with Acute Myeloid Leukemia. Cancer, 113, 1370-1378.
https://doi.org/10.1002/cncr.23691
|
[18]
|
Yamauchi, K. and Yasuda, M. (2002) Comparison in Treatments of Nonleukemic Granulocytic Sarcoma: Report of Two Cases and a Review of 72 Cases in the Literature. Cancer, 94, 1739-1746. https://doi.org/10.1002/cncr.10399
|
[19]
|
Florou, V. and Wilky, B.A. (2018) Current and Future Directions for Angiosarcoma Therapy. Current Treatment Options in Oncology, 19, Article No.: 14. https://doi.org/10.1007/s11864-018-0531-3
|
[20]
|
Shelley, M.D., Mason, M.D. and Kynaston, H. (2010) Intravesical Therapy for Superficial Bladder Cancer: A Systematic Review of Randomised Trials and Meta-Analyses. Cancer Treatment Reviews, 36, 195-205.
https://doi.org/10.1016/j.ctrv.2009.12.005
|
[21]
|
Bielack, S.S., Erttmann, R., Kempf-Bielack, B., et al. (1996) Impact of Scheduling on Toxicity and Clinical Efficacy of Doxorubicin: What Do We Know in the Mid-Nineties? European Journal of Cancer, 32A, 1652-1660.
https://doi.org/10.1016/0959-8049(96)00177-3
|
[22]
|
Skubitz, K.M. and Haddad, P.A. (2005) Paclitaxel and Pegylated-Liposomal Doxorubicin Are Both Active in Angiosarcoma. Cancer, 104, 361-366. https://doi.org/10.1002/cncr.21140
|
[23]
|
Lan, T.-Y., Lin, D.-T., Tien, H.-F., et al. (2009) Prognostic Factors of Treatment Outcomes in Patients with Granulocytic Sarcoma. Acta Haematologica, 122, 238-246. https://doi.org/10.1159/000253592
|
[24]
|
Chevallier, P., Mohty, M., Lioure, B., et al. (2008) Allogeneic Hematopoietic Stem-Cell Transplantation for Myeloid Sarcoma: A Retrospective Study from the SFGM-TC. Journal of Clinical Oncology, 26, 4940-4943.
https://doi.org/10.1200/JCO.2007.15.6315
|
[25]
|
林桂真. 自体与异体造血干细胞移植后造血系统重建的状况与差异分析[J]. 新医学, 2005, 36(5): 277-278.
|
[26]
|
Avni, B. and Koren-Michowitz, M. (2011) Myeloid Sarcoma: Current Approach and Therapeutic Options. Therapeutic Advances in Hematology, 2, 309-316. https://doi.org/10.1177/2040620711410774
|
[27]
|
He, J., Zhu, L., Ye, X., et al. (2014) Clinical Characteristics and Prognosis of Nonleukemic Myeloid Sarcoma. The American Journal of the Medical Sciences, 347, 434-438. https://doi.org/10.1097/MAJ.0b013e31829ca859
|